Search International and National Patent Collections

1. (WO2017184562) CMV NEUTRALIZING ANTIGEN BINDING PROTEINS

Pub. No.:    WO/2017/184562    International Application No.:    PCT/US2017/028062
Publication Date: Fri Oct 27 01:59:59 CEST 2017 International Filing Date: Wed Apr 19 01:59:59 CEST 2017
IPC: A61K 39/00
A61K 39/245
A61K 39/395
A61K 39/42
C12N 7/00
C12P 21/00
Applicants: MERCK SHARP & DOHME CORP.
THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
FU, Tong-Ming
TANG, Aimin
WANG, Dai
AN, Zhiqiang
ZHANG, Ningyan
HA, Sha
Inventors: FU, Tong-Ming
TANG, Aimin
WANG, Dai
AN, Zhiqiang
ZHANG, Ningyan
HA, Sha
Title: CMV NEUTRALIZING ANTIGEN BINDING PROTEINS
Abstract:
The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). The antigen binding proteins of the invention are useful as a prophylactic and/or therapeutic agent for preventing and/or treating CMV infections in a patient in need thereof. Also encompassed by the invention are pharmaceutical compositions comprising the antigen binding proteins of the invention and a pharmaceutically acceptable carrier. The invention further relates to methods of using the antigen binding proteins and pharmaceutical compositions of the invention for the prevention or treatment of CMV infection in patients in need thereof.